Streamlined Resin Y90 Radiation Segmentectomy for Small HCC

Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Sep 25, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older
• • Has focal Hepatocellular Carcinoma and is deemed to benefit from Yttrium-90 radioembolization by the institutional multidisciplinary tumor board
• Exclusion Criteria:
• • All subjects meeting any of the exclusion criteria at baseline will be excluded from study participation.
• • The presence of trans-jugular intrahepatic portosystemic shunt
• • Total bilirubin level \> 3.0 mg/dL
• • Serum albumin level \< 2.5 g/dL
• • Aspartate and alanine aminotransferase levels no greater than five times the normal level
• • Life expectancy \< 12 weeks
• • Eastern Cooperative Oncology Group performance status \> 2
• • Patients with chronic lung disease requiring supplemental oxygen at baseline or baseline SpO2 of \<92%
• • Patients that have tumors with central anatomical locations close the hepatic hilum or caudate lobe.
• • Patients with macrovascular invasion on baseline imaging
• • Known hypersensitivity to iodinated contrast agents or to any component of iodinated contrast agents refractory to standard medications (antihistamines, steroids)
• • Impaired kidney function (glomerular filtration rate \< 30 as approximated using serum creatinine levels) unless anuric and on dialysis.
• • Any woman who is pregnant or has reason to believe she is pregnant (the possibility of pregnancy has to be excluded by negative urine β-HCG results, obtained within 48 hours prior to the treatment or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of 1 year without menses)